

Review Article



OPEN ACCESS

Received: Nov 30, 2022
Revised: Jan 17, 2023
Accepted: Jan 29, 2023
Published online: Feb 17, 2023

*Correspondence to

Gap Ryol Lee

Department of Life Science, Sogang University,
35 Baekbeom-ro, Mapo-gu, Seoul 04107,
Korea.

Email: grlee@sogang.ac.kr

Copyright © 2023. The Korean Association of Immunologists

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID iDs

Gap Ryol Lee

<https://orcid.org/0000-0002-6412-9482>

Conflict of Interest

The authors declare no potential conflicts of interest.

Abbreviations

AMPK, AMP-activated protein kinase; APC, antigen-presenting cell; DC, dendritic cell; EAE, experimental autoimmune encephalomyelitis; LCR, locus control region; OXPHOS, oxidative phosphorylation; Phd, prolyl-4-hydroxylase domain; pTreg, regulatory T cell in the periphery; scRNA-seq, single cell RNA sequencing; Tfh, follicular helper T; Tr1, type-1 regulatory T; tTreg, regulatory T cell development in the thymus; Vhl, von Hippel-Lindau.

Molecular Mechanisms of T Helper Cell Differentiation and Functional Specialization

Gap Ryol Lee

Department of Life Science, Sogang University, Seoul 04107, Korea

ABSTRACT

Th cells, which orchestrate immune responses to various pathogens, differentiate from naïve CD4 T cells into several subsets that stimulate and regulate immune responses against various types of pathogens, as well as a variety of immune-related diseases. Decades of research have revealed that the fate decision processes are controlled by cytokines, cytokine receptor signaling, and master transcription factors that drive the differentiation programs. Since the Th1 and Th2 paradigm was proposed, many subsets have been added to the list. In this review, I will summarize these events, including the fate decision processes, subset functions, transcriptional regulation, metabolic regulation, and plasticity and heterogeneity. I will also introduce current topics of interest.

Keywords: Helper T cell; T-lymphocyte subset; Cell differentiation; Adaptive immune response; Transcription factors; Cytokines

INTRODUCTION

Pathogens can infect many different tissues and cellular compartments, and the life cycles of these pathogens can vary considerably. To overcome this, the host immune system has developed pathogen-specific strategies. For example, Th cells (effector CD4 T cells) orchestrate immune responses against many different pathogens (1-4). Naïve CD4 T cells recirculate via the blood and lymphatic systems, gathering information about pathogens by binding to antigens presented by dendritic cells (DCs) in lymphoid tissues. DCs also secrete cytokines when they present these pathogen-specific antigens to naïve CD4 T cells, thereby triggering differentiation pathways (1-4). Activated CD4 T cells proliferate and differentiate into different immune cell subsets, which determine the type of immune response (1-4). Research in the field of Th cell differentiation and function began about 30 years ago, and it is still progressing. In this review, I will summarize the basic principles that govern Th cell differentiation (Fig. 1). Other topics in this field, including the microbiota and plasticity/heterogeneity, will be covered by other articles in this issue.




Figure 1. Schematic diagram of Th cell differentiation. Th cell differentiation pathway is determined by inducer cytokines that are present during T cell activation. The cytokine signaling activates STAT or SMAD, which in turn induces master transcription factors. Master transcription factors drive the subset-specific differentiation programs. Th cell proliferation and differentiation are also influenced by nutrient or metabolites.

BRIEF HISTORY OF Th SUBSETS

For a long time, Th cells were regarded as cells that aid activation of B cells and macrophages by producing cytokines. In 1986, Mosmann and colleagues (5) published a seminal work showing that Th cells comprise 2 distinct cell types based on their cytokine profiles, namely, Th1 and Th2. The different cytokines produced by these cell types lead to mutually exclusive functional properties (5). Th1 cells activate macrophages and mediate immune responses against intracellular pathogens, while Th2 cells stimulate B cells (5). Identification of Th cell heterogeneity and differences in functional properties was a major conceptual advance in the field, and triggered further study of the molecular mechanisms that regulate the fate-determining processes and functional properties. These efforts led to identification of cytokines, signaling pathways, and transcription factors as determinants of Th1 and Th2 subset differentiation. In 2005, Th17 cells were identified and proposed as an independent subset (6-8). Th17 cells induce inflammation and mediate immune responses against extracellular bacteria and fungi (9,10). Another independent subset, called follicular helper T (Tfh) cells, was also identified (11-13). Tfh cells reside in the germinal centers of lymphoid tissue and interact with B cells to trigger maturation. It was thought that B cell stimulation was the role of Th2 cells; however, this is now thought to be the role of Tfh cells. In addition to activator cells, repressor cell types have also been identified; these are termed Treg cells (14-16). Many other subsets have also been identified, including IL-9-producing Th9 cells, IL-22-producing Th22 cells, and IL-10 producing type-1 regulatory T (Tr1) cells. Th9, Th22, and Tr1 cells will not be covered in this review because our understanding of their functions and roles is still in its infancy.

Th CELL FUNCTIONS

Effector CD4 T cells either stimulate or repress other immune cells. The most important mediators of these functions are cytokines (1-4). Th1 cells produce IFN- γ , which stimulates macrophages and CTLs. Stimulated macrophages kill intracellular pathogens by activating microbicidal mechanisms, including facilitation of fusion of phagosomes with lysosomes, activation of NADPH oxidase, and generation of reactive oxygen species (17). Activation of CTL requires the help of Th1 cells via secretion of IFN- γ and CD40L signaling, which trigger CTL differentiation. Th2 cells produce IL-4, IL-5, and IL-13, which mobilize or stimulate eosinophils, basophils, and mast cells to combat helminthic parasites (18). IL-13 also stimulates intestinal epithelial cells to increase cell turnover and movement, as well as acting on smooth muscle cells in the intestine to increase contractility, all of which help to remove parasites from the gut. Th17 cells produce IL-17A, IL-17F, and IL-22, which stimulate epithelial cells, fibroblasts, and stromal cells to produce GM-CSF, recruit neutrophils, and induce inflammation, thereby mediating immune responses against extracellular bacteria and fungi (9,10). Tfh cells produce IL-21 and activate B cells in the germinal center to induce maturation via somatic hypermutation and class-switch recombination (19). Treg cells inhibit effector T cell and B cell responses, as well as innate immune responses (20). Treg cells produce IL-10, TGF- β , and IL-35 to inhibit immune responses, although they can use other mechanisms too. Treg cells express high amounts of IL2R α on their surface, leading to deprivation of IL-2, which is required for growth of effector CD4 T cells. Treg cells express coinhibitory receptors such as Ctla-4 and Lag3, which interfere with the interaction with costimulatory molecules and MHC class II molecules expressed by antigen-presenting cells (APCs), thereby preventing T cell activation (21,22). Treg cells also kill CD4 T cells directly by secreting cytotoxins. They also express high amounts of ectonucleotidases such as CD39 and CD73, leading to production of immunosuppressive adenosine, which promotes T cell anergy (23). Although Treg development in the thymus (tTreg) and Treg in the periphery (pTreg) cells have overlapping functions, tTregs are more specialized at preventing autoimmune responses against self-antigens, whereas pTregs are more specialized in inducing tolerance to foreign antigens.

Each CD4 T cell subset cross regulates other subsets. For example, Th1 cells inhibit Th2 and Th17 cell differentiation by suppressing expression of IL-4 and IL-17, respectively (7,24). Th2 cells repress Th1 differentiation by inhibiting IL-12R β 2 and IL-17 expression, respectively (7,25). Tfh cells inhibit differentiation of other subsets via Bcl6-mediated repression of *Prdml1* (which encodes Blimp-1) expression (26,27).

In addition to the induction of protective immunity against infectious agents, Th cells are responsible for the pathology of many other diseases caused by aberrant immune responses (1-4). For example, Th1 and Th17 cells play critical roles in rheumatoid arthritis, type I diabetes, and multiple sclerosis; Th2 cells in allergic diseases such as asthma, rhinitis, and allergic dermatitis; and Treg cells in autoimmune disease, allergy, and cancer. Thus, regulating subset-specific functions is an effective strategy for treating these immune-related diseases. Indeed, based on this knowledge, many therapeutic strategies have been, or are being, developed (28,29).

SIGNAL TRANSDUCTION AND TRANSCRIPTIONAL REGULATION

Naïve CD4 T cells differentiate into various subsets of effector cells when they recognize their cognate antigens presented in conjunction with MHC II molecules on the surface of DCs in lymphoid tissues (1-3). These subsets include Th1, Th2, Th17, Tfh, and Treg cells (1-3). The fates of these subsets are determined by the cytokines (produced mainly by APCs) present in the environment at the time of activation (1-3). The cytokines bind to their cognate receptors on naïve CD4 T cells and activate the STAT or SMAD pathway (1-3). Th1 cell differentiation is induced by IL-12 or IFN- γ , which activate Stat4 or Stat1, respectively (1-3). Th2 cell differentiation is induced by IL-4, which activates Stat6 (1-3). Th17 cell differentiation is induced by TGF- β plus IL-6 (or IL-21), which activate Stat3 (1-3). Tfh cell differentiation is induced by IL-21, which also activates Stat3 (1-3). Treg cells are rather different in that they can be generated during T cell development in the thymus (tTreg cells) or can differentiate from naïve CD4 pTreg cells (1-3). *In vitro*, Treg cells can be differentiated by TGF- β , which activates Smad2 and Smad3 (1-3).

STAT proteins enter the nucleus and induce global epigenetic changes as well as expression of master transcription factors which drive differentiation programs (1-4). T-bet drives the Th1 program, Gata-3 drives the Th2 program, Ror γ t drives the Th17 program, Bcl6 drives the Tfh program, and Foxp3 drives the Treg program. These transcription factors induce expression of a variety of genes required for differentiation, and for the effector functions, of each subset. Division of the roles played by STATs and the master transcription factors is the focus of much interest. Although both factors are important for differentiation, it seems likely that STATs act as pioneering factors that shape global enhancer landscapes and gene expression patterns, whereas master transcription factors regulate a limited set of genes that is required for subset-specific differentiation and function (30,31).

Although master transcription factors drive the differentiation program in Th cells, many other transcription factors play important roles in the process (32,33). In addition to the master transcription factors, Irfl, Runx3, Hlx, Ets-1, Nfatc1, and Bhlhe40 play important roles in Th1 cell differentiation; c-Maf, Notch/CSL, IRF4, Gfi-1, and Yy1 in Th2 differentiation; Irf4, Batf, and Runx1 in Th17 differentiation; and Runx1, Nr4a2, Foxo family members, Satb1, and Helio in Treg differentiation (32,33). These transcription factors form a coordinated network that drives the differentiation programs (34-36), even in the absence of master transcription factors (36). The roles of these transcription factors depend on individual factors. In general, these factors either enhance transcription, induce changes in epigenetic status, or promote organization of the relevant genes or gene loci within the genome (32,33).

EPIGENETIC REGULATION

Along with transcription factors, the genetic loci of characteristic cytokine genes have been investigated extensively with respect to their role in regulating Th cell differentiation (37,38). This is due in part to the fact that the differentiation process is easily controlled *in vitro* by cytokines, enabling investigation of cell fates within a short period of time. Such studies have reported interesting findings: 1) epigenetic changes accompany gene expression during differentiation; 2) poised state of cytokine loci even before differentiation; 3) coordinate expression of cytokine genes; 4) inter-chromosomal interactions between 2 opposing loci; and 5) insulation of cytokine loci.

Epigenetic changes during Th cell differentiation

Marked changes in gene expression occur during CD4 T cell activation and differentiation. Many of the genes expressed by activated T cells are required for cell division. Since naïve T cells are in a quiescent state, transition to actively dividing cells requires systemic changes in gene expression. Yet more genes are required for subset-specific effector functions; for example, genes encoding cytokines that mediate the effector functions of a particular subset. Not surprisingly, naïve CD4 T cells undergo epigenetic changes such as increased accessibility by DNase I, histone acetylation, and DNA methylation (37,38). *Ifng* and the Th2 cytokine locus (the *Il4-Il13-Il5* locus) show subset-specific epigenetic changes. During Th1 differentiation, the *Ifng* locus opens, but the Th2 cytokine locus remains closed. Likewise, the Th2 cytokine locus opens during Th2 differentiation, but the *Ifng* locus remains closed. This subset-specific chromatin modification is influenced by master transcription factors such as T-bet and Gata-3. Thus, one of the roles of these transcription factors is to open the chromatin at the loci of subset-specific genes to make it “competent” for expression of these genes.

Poised state of cytokine loci before differentiation

Certain genetic loci, such as the *Ifng* locus, are demethylated even before Th1 differentiation. This hypomethylation pattern seems to be established early during T cell development, including that of naïve CD4 T cells, suggesting that these loci are predisposed to expression (37,38). During Th1 differentiation, this demethylation pattern at the *Ifng* locus is preserved; however, the locus becomes methylated during Th2 differentiation. Genome-wide studies of the epigenetic status of chromatin and gene expression in CD4 T cells revealed that the histone modification status of key cytokine and transcription factor loci correlates strongly with gene expression patterns (39). Interestingly, this study also found that *Tbx21* and *Gata3* loci contain both active (H3K4me3) and suppressive (H3K27me3) histone marks (39). This bivalent status with respect to histone marks also predispose gene expression, suggesting that cells are preparing for rapid changes in gene expression that occur during activation and differentiation. The poised status of multiple key genetic loci facilitates easy conversion from one differentiated state to another.

Coordinate expression of cytokine genes

The *Ifng* locus and the Th2 cytokine locus are regulated by promoters, enhancers, and silencers in the same manner as other genetic loci (37,38). Since the *Il4*, *Il13*, and *Il5* genes are clustered, it is of interest to see whether they are coordinately regulated in Th2 cells. One of the regulatory elements that exerts coordinate expression of clustered genes is the locus control region (LCR), best exemplified by the β -globin LCR (40). The LCR is defined as a sequence that enables copy number-dependent expression in transgenic mice (40). The Th2 cytokine locus contains an LCR, called the Th2 LCR, which is interspersed in the intron regions of the *Rad50* gene located between the *Il13* and *Il5* genes (41). The Th2 LCR undergoes epigenetic changes during Th2 differentiation by recruiting GATA3 and other transcription factors such as Yy1, Stat6, Satb1, and Irf4 (42-44). This process is essential for Th2 cytokine expression since deletion of the Th2 LCR or its components abolishes Th2 cytokine expression (42,45,46). The Th2 LCR induces chromosomal looping to facilitate interactions with the promoters of Th2 cytokine genes, thereby forming a basis for coordinated regulation (47).

Inter-chromosomal interactions between 2 opposing loci

Chromosomal interactions occur not only intra-chromosomally, but also inter-chromosomally. Chromosomal interaction between 2 different chromosomes has been suggested for long time, but it was proved experimentally in the study of *Ifng* and Th2 loci,

shedding light on a novel mechanism of gene regulation (48). Although they are located on different chromosomes, *Ifng* and RHS6, a component of the Th2 LCR, in naïve CD4 T cells interact with each other. This physical interaction seems to maintain a poised state for expression of each gene until the cell is activated, since this interaction is replaced with intrachromosomal interactions upon Th2 cell differentiation (48). In naïve CD4 T cells, RHS6 also interacts with the *Il17* promoter through Oct-1 and CTCF, suggesting occurrence of inter-chromosomal interactions among multiple chromosomes (49). When Oct-1, CTCF, or the interacting genetic loci are deficient, the interaction does not occur and expression of *Il17* increases (49), supporting its role in cytokine gene regulation.

Insulation of cytokine loci

The *Ifng* locus is located about 40 kb downstream of the *IL22* gene in humans and 245 kb downstream of the *Il22* gene in mice. Since *Il22* is a Th17-specific gene, expression of *Ifng* and *Il22* should be regulated separately. Indeed, an insulator sequence between these gene loci was identified by genome-wide screening of CTCF binding sites and cohesion binding sites (50,51). The *Ifng* locus is insulated by -70 and +66 boundary elements, which contain CTCF and the cohesion component Rad21 (50,51). Although recruitment of CTCF to the -70 site is conserved in naïve, Th1, and Th2 cells, CTCF recruitment to the *Ifng* intronic region and +66 site is specific to Th1 cells (50,51), suggesting that this insulator sequence, and its binding to CTCF, may play a role in forming the intra-chromosomal loops needed for the *Ifng* gene transcription.

PLASTICITY AND HETEROGENEITY

I will provide a very brief overview of this topic as it is covered in depth by another article in this issue. Initially, the status of Th1 and Th2 cells was thought to be stable and terminally differentiated; this is because reversal between subsets cannot be induced after long-term culture (52), and production of specific cytokines seems to be stably maintained (53). However, later studies showed that Th subsets are not permanently differentiated; rather they can differentiate into another subset under certain circumstances. This phenomenon is called plasticity (54,55). Early *in vitro* studies suggested that forced expression of master regulators by already differentiated cells induces alternative differentiation pathways (55). For example, Th1 cells produce IL-4 upon transfection with Gata-3, and Th2 cells can express IFN- γ upon transfection of T-bet. A fate-mapping study using a mouse model of experimental autoimmune encephalomyelitis (EAE) revealed that most cells producing IFN- γ previously expressed IL-17A (56). Studies in animal models of diabetes and cancer show that Th17 cells acquire Th1-like properties (57,58).

In addition to plasticity, CD4 T cells show functional heterogeneity. Cells co-expressing T-bet and ROR γ t are present in the gut and inflamed brain tissue (56,59). These cells express both IFN- γ and IL-17, and are thought to play an important role in immune responses to *Mycobacterium tuberculosis* (60). Treg cells often co-express T-bet, Gata3, or Ror γ t. T-bet-expressing Treg cells inhibit type I immune responses (61). Gata3 is frequently co-expressed with Foxp3 by Treg cells and is thought to help control Th2-type immune response (62). Treg cells co-expressing Irf4 or Stat3 control Th2- and Th17-mediated immune responses, respectively (63,64). Thus, co-expression of transcription factors by other subsets seems to endow Treg cells with the ability to control specific effector functions.

The plasticity and heterogeneity of Th subsets modifies and expands the characteristics of each subset. Plasticity is thought to be an adaptation to a changing environment or to pathogens. Since some pathogens change their habitats (e.g., by infecting different cells/organs) and their virulence strategy during their life cycle, the immune system needs to change its defensive strategies to combat them.

METABOLIC REGULATION

When naïve CD4 T cells are activated and differentiate into effector cells, they undergo drastic changes in their metabolic programs (1,65-67). During this process, differentiating and proliferating cells require energy, as well as the building blocks to synthesize DNA, RNA, proteins, and lipids. Effector subsets of Th cells, namely, Th1, Th2, and Th17 cells, rely more heavily on glycolysis than Treg cells (1,34,65,66). Most cells generate ATP via oxidative phosphorylation (OXPHOS), which occurs in the mitochondria. However, rapidly dividing cells such as cancer cells use aerobic glycolysis instead of OXPHOS to generate ATP. Although it generates less ATP than OXPHOS, aerobic glycolysis can provide many of the materials required for biosynthesis in cells proliferating under hypoxic conditions. This phenomenon, called the “Warburg effect,” also occurs in effector T cells, which are rapidly dividing cells. Tfh cells also show enhanced glycolysis, but cell-autonomous IL-2 inhibits the differentiation and metabolic programs of Tfh cells. Th17 cells also use glutaminolysis and fatty acid synthesis programs, whereas fatty acid synthesis antagonizes differentiation of Treg cells. By contrast, Treg cells rely on mitochondrial activity for their differentiation, homeostasis, and function.

Since Th cell differentiation requires metabolic reprogramming, factors that regulate this process affect Th cell differentiation (65). These factors include 1) nutrients/metabolites, 2) transcription factors, and 3) signaling molecules.

Nutrients/metabolites

Glucose is a readily available nutrient that provides energy to activated and proliferating T cells, as well as building blocks for nucleic acids, proteins, lipids, and carbohydrates. Glucose-6-phosphate, the first intermediate of glycolysis, can be converted to fructose-6-phosphate to yield pyruvate, which is used to synthesize glycogen, or shuttled to synthesize purines and pyrimidines via the pentose phosphate pathway. TCR and/or costimulatory signaling through CD28 triggers rapid uptake of glucose by upregulating the glucose transporter Glut1 and by increasing glycolytic flux (1,65-67). Thus, activated CD4 T cells are highly dependent on glucose uptake. Indeed, Th1 and Th17 cells have an increased glycolytic rate. Chemical or genetic inhibition of specific steps within the glycolytic pathway leads to a marked reduction in effector T cell proliferation and cytokine production. Deprivation of glucose impairs T cell activation and survival, highlighting the importance of glucose for the T cell activation and differentiation processes (1,34,65,66). Glucose deprivation also inhibits IFN- γ production, as well as reducing production of phosphoenolpyruvate, which supports Ca²⁺/NFAT signaling required for glycolytic reprogramming in T cells (1,65-67). Unlike effector T cell subsets, Treg cells are not affected by Glut1 deficiency (1,34,65,66). Blocking glycolysis with 2-DG, an inhibitor of hexokinase (an enzyme that regulates the rate limiting step of glycolysis), inhibits differentiation of CD4 and CD8 T cells into effector cells (1,65-67). Deficiency of lactate dehydrogenase A, an enzyme that converts lactate to pyruvate, inhibits ATP generation and PI3K/Akt activation, thereby repressing T cell activation (68). High levels of glycolytic metabolism inhibit induction of Foxp3, instead inducing Th17 cell differentiation (69).

Fatty acid metabolism is a critical part of T cell differentiation. Fatty acid oxidation is essential for Treg cell generation and function, and for making membrane components by proliferating effector T cells, including Th1, Th2, and Th17 cells (70). Proliferating activated T cells show increased fatty acid synthesis, with a concomitant reduction in fatty acid oxidation. Fatty acid metabolism is important for the balance between Th17 and Treg cells: fatty acids aid the generation and function of Treg cells, while controlling the pathogenicity of Th17 cells (70).

Transcription factors

Myc, induced by TCR stimulation, is essential for metabolic reprogramming of T cell activation and function. Myc (71), which plays an essential role in glycolysis and glutaminolysis in activated T cells, induces Glut1 and several glycolytic enzymes (71). When Myc is ablated, glycolysis is impaired, resulting in decreased T cell activation and growth (72). Myc also stimulates glutaminolysis by increasing expression of glutaminase and glutamine transporters (73).

HIF-1 α plays an important role in Th cell differentiation and function (74) by enhancing Th17 cell differentiation via stimulation of *Il17* gene transcription while reducing Treg cell generation via Foxp3 degradation (75). Conditional deletion of HIF-1 α causes resistance to EAE, with reduced infiltration of the CNS by Th17 cells (69). In addition, HIF-1 α induces glycolysis under hypoxic conditions. The oxygen-sensing function is regulated by 2 proteins; the von Hippel-Lindau (Vhl) complex supports and prolyl-4-hydroxylase domain (Phd) proteins oppose the function. Upon activation, *Vhl*-deficient T cells show augmented glycolysis but reduced mitochondrial oxidative metabolism, leading to enhanced effector programming, effector/memory cell differentiation, and cell death (76,77). *Phd*-deficient CD4 T cells, however, show increased effector cell differentiation but decreased Treg cell differentiation (78).

Signaling molecules

The mTOR is a serine/threonine kinase that transmits signals from the PI3K-Akt pathway. mTOR forms 2 functionally distinct complexes, mTORC1 and mTORC2, and is essential for regulating glucose metabolism and upregulating glycolysis. It is also required for effector T cell differentiation; indeed, mTOR deficiency causes failure of effector T cell differentiation and leads to Treg cell generation instead (79). mTORC1 and mTORC2 play distinct roles during differentiation of Th subsets. CD4 T cells lacking mTORC1 activity due to the absence of one of its components (Rheb) failed to generate Th1 and Th17 cells (80), whereas those lacking mTORC2 activity due to the absence of Rictor failed to generate Th2 cells (80,81). Excessive mTOR activity caused by *Pten*-deficiency reduces the stability of Treg cells, leading to uncontrolled Th1 and Tfh cell responses (82,83).

AMP-activated protein kinase (AMPK) is a glucose-sensitive metabolic sensor that regulates mRNA translation and glutamine-dependent mitochondrial metabolism (84). AMPK promotes catabolic processes but inhibits anabolic processes. It also promotes OXPHOS, mitochondrial biogenesis, fatty acid oxidation, and autophagy, but inhibits glycolysis, glutaminolysis, and glycogen and fatty acid synthesis (84). AMPK promotes energy conservation by T cells, as well as maintaining T cell bioenergetics and viability (84). It also negatively regulates effector Th cell differentiation by inhibiting mTORC1 activity. *Ampka1*-deficient T cells show reduced metabolic plasticity and mitochondrial bioenergetic when glucose is limited (84). Under glucose-limiting conditions, reduced expression of IFN- γ mRNA and protein affects Th1 differentiation. By contrast, AMPK induces differentiation of naïve CD4 T into Treg cells (85).

CHALLENGES TO THE Th SUBSET PARADIGM

The paradigm of Th subsets has contributed greatly to our understanding of the immune system. The paradigm divides immune responses into categories, and provides a simple framework for understanding otherwise complex phenomena. Based on this paradigm, many immune-related diseases have been categorized as type I, type II, and type III diseases. This categorization is also applied to innate immune cells, such as innate lymphoid cells and macrophages. The paradigm was originally proposed, and mainly studied, in the context of *in vitro*-differentiated CD4 T cells, generation of which requires excessive amounts of cytokines and neutralizing antibodies.

The plasticity and heterogeneity of Th cells modifies their functions rather elegantly without necessarily challenging the classical view of Th cell subsets, which states that these subsets are terminally differentiated and stable. Recent technological advances such as single cell RNA sequencing (scRNA-seq) and CyTOF have made it possible to analyze gene expression at the single cell level. Studies using these technologies show that effector Th cells are much more heterogeneous than the paradigm suggests.

scRNA-seq and computational analysis show that Th17 cells isolated from animal models of autoimmune diseases are heterogeneous and show a spectrum of cellular states (86,87). Tortola et al. (88) used CyTOF to analyze expression of subset-specific marker proteins expressed by *in vitro*-differentiated Th cells and by Th cells in animal disease models. They found that effector Th cells are far more heterogeneous than expected, even under controlled stimulation conditions. Kiner et al. (89) analyzed gut CD4 T cells using scRNA-seq and ATAC-seq. Surprisingly, they found that CD4 T cells do not follow the classic subset-specific gene expression pattern. IFN- γ and IL-17A are expressed by most effector cells, many of which co-express both genes (89). Transcriptional and epigenetic patterns are determined by infectious agents rather than by cytokine and master transcription factor signatures (89). scRNA-seq followed by trajectory analysis revealed that Th1 cells and Tfh cells bifurcate during their differentiation in malaria infection model (90). These results challenge the Th subset paradigm, and suggest that Th cells exist in a heterogeneous state of differentiation, which may change according to the environment. Thus, more studies in this area are needed.

CONCLUSIONS AND PERSPECTIVES

Th cells play essential roles in coordinating immune responses to different pathogens. They are also responsible for many immune pathologies. Thus, research on Th cells (either the fundamental mechanisms underlying differentiation and function, or therapeutic applications based on the results of such studies) is ongoing. New technological advances will speed up progress. For example, scRNA-seq can reveal detailed gene expression patterns in individual cells within a large population, providing information about possible differentiation pathways. CRISPR/Cas9 technology enables functional study of genes of interest on a large scale, either *in vitro* or *in vivo*. Introduction of the concept of super-enhancers, which are defined as regulatory regions that are highly enriched in transcription factors and activating/suppressive epigenetic marks, will facilitate more rapid study of regulatory regions, since they can be identified by genome wide approaches and bioinformatics analysis. These new technologies or concepts will enable comprehensive analysis of the molecular mechanisms underlying these processes, while challenging the

current paradigm. I anticipate and hope that more and more new and interesting findings about the underlying molecular mechanisms will come to light, and that we will make progress in the treatment of difficult-to-cure diseases.

ACKNOWLEDGEMENTS

This work was supported by the National Research Foundation of Korea (NRF) grants funded by the Korean government (2021K2A9A2A06048161, 2022R1A2B5B03001840, 2022R1A4A5032688 to GRL).

REFERENCES

1. Saravia J, Chapman NM, Chi H. Helper T cell differentiation. *Cell Mol Immunol* 2019;16:634-643.
[PUBMED](#) | [CROSSREF](#)
2. O'Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4⁺ T cells. *Science* 2010;327:1098-1102.
[PUBMED](#) | [CROSSREF](#)
3. Murphy KM, Ouyang W, Farrar JD, Yang J, Ranganath S, Asnagli H, Afkarian M, Murphy TL. Signaling and transcription in T helper development. *Annu Rev Immunol* 2000;18:451-494.
[PUBMED](#) | [CROSSREF](#)
4. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). *Annu Rev Immunol* 2010;28:445-489.
[PUBMED](#) | [CROSSREF](#)
5. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. *J Immunol* 1986;136:2348-2357.
[PUBMED](#) | [CROSSREF](#)
6. Bettelli E, Kuchroo VK. IL-12- and IL-23-induced T helper cell subsets: birds of the same feather flock together. *J Exp Med* 2005;201:169-171.
[PUBMED](#) | [CROSSREF](#)
7. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. Interleukin 17-producing CD4⁺ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. *Nat Immunol* 2005;6:1123-1132.
[PUBMED](#) | [CROSSREF](#)
8. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. *Nat Immunol* 2005;6:1133-1141.
[PUBMED](#) | [CROSSREF](#)
9. Patel DD, Kuchroo VK. Th17 cell pathway in human immunity: lessons from genetics and therapeutic interventions. *Immunity* 2015;43:1040-1051.
[PUBMED](#) | [CROSSREF](#)
10. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. *Immunity* 2008;28:454-467.
[PUBMED](#) | [CROSSREF](#)
11. Chtanova T, Tangye SG, Newton R, Frank N, Hodge MR, Rolph MS, Mackay CR. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. *J Immunol* 2004;173:68-78.
[PUBMED](#) | [CROSSREF](#)
12. Nurieva RI, Chung Y, Hwang D, Yang XO, Kang HS, Ma L, Wang YH, Watowich SS, Jetten AM, Tian Q, et al. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. *Immunity* 2008;29:138-149.
[PUBMED](#) | [CROSSREF](#)
13. Kim CH, Lim HW, Kim JR, Rott L, Hillsamer P, Butcher EC. Unique gene expression program of human germinal center T helper cells. *Blood* 2004;104:1952-1960.
[PUBMED](#) | [CROSSREF](#)

14. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. *J Immunol* 1995;155:1151-1164.
[PUBMED](#) | [CROSSREF](#)
15. Veldhoen M, Uyttenhove C, van Snick J, Helmby H, Westendorf A, Buer J, Martin B, Wilhelm C, Stockinger B. Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. *Nat Immunol* 2008;9:1341-1346.
[PUBMED](#) | [CROSSREF](#)
16. Dardalhon V, Awasthi A, Kwon H, Galileos G, Gao W, Sobel RA, Mitsdoerffer M, Strom TB, Elyaman W, Ho IC, et al. IL-4 inhibits TGF- β -induced Foxp3⁺ T cells and, together with TGF- β , generates IL-9⁺ IL-10⁺ Foxp3⁺ effector T cells. *Nat Immunol* 2008;9:1347-1355.
[PUBMED](#) | [CROSSREF](#)
17. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. *Nat Rev Immunol* 2011;11:723-737.
[PUBMED](#) | [CROSSREF](#)
18. Maizels RM, Pearce EJ, Artis D, Yazdanbakhsh M, Wynn TA. Regulation of pathogenesis and immunity in helminth infections. *J Exp Med* 2009;206:2059-2066.
[PUBMED](#) | [CROSSREF](#)
19. Shulman Z, Gitlin AD, Weinstein JS, Lainez B, Esplugues E, Flavell RA, Craft JE, Nussenzweig MC. Dynamic signaling by T follicular helper cells during germinal center B cell selection. *Science* 2014;345:1058-1062.
[PUBMED](#) | [CROSSREF](#)
20. Kitagawa Y, Sakaguchi S. Molecular control of regulatory T cell development and function. *Curr Opin Immunol* 2017;49:64-70.
[PUBMED](#) | [CROSSREF](#)
21. Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Levitsky HI, et al. Role of LAG-3 in regulatory T cells. *Immunity* 2004;21:503-513.
[PUBMED](#) | [CROSSREF](#)
22. Paust S, Lu L, McCarty N, Cantor H. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. *Proc Natl Acad Sci U S A* 2004;101:10398-10403.
[PUBMED](#) | [CROSSREF](#)
23. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enyoloji K, Linden J, Oukka M, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. *J Exp Med* 2007;204:1257-1265.
[PUBMED](#) | [CROSSREF](#)
24. Djuretic IM, Levanon D, Negreanu V, Groner Y, Rao A, Ansel KM. Transcription factors T-bet and Runx3 cooperate to activate *Ifng* and silence *Il4* in T helper type 1 cells. *Nat Immunol* 2007;8:145-153.
[PUBMED](#) | [CROSSREF](#)
25. Szabo SJ, Dighe AS, Gubler U, Murphy KM. Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 cells. *J Exp Med* 1997;185:817-824.
[PUBMED](#) | [CROSSREF](#)
26. Johnston RJ, Poholek AC, DiToro D, Yusuf I, Eto D, Barnett B, Dent AL, Craft J, Crotty S. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. *Science* 2009;325:1006-1010.
[PUBMED](#) | [CROSSREF](#)
27. Nurieva RI, Chung Y, Martinez GJ, Yang XO, Tanaka S, Matskevitch TD, Wang YH, Dong C. Bcl6 mediates the development of T follicular helper cells. *Science* 2009;325:1001-1005.
[PUBMED](#) | [CROSSREF](#)
28. Lee JB, Kim HR, Ha SJ. Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy. *Immune Netw* 2022;22:e2.
[PUBMED](#) | [CROSSREF](#)
29. Jung SM, Kim WU. Targeted immunotherapy for autoimmune disease. *Immune Netw* 2022;22:e9.
[PUBMED](#) | [CROSSREF](#)
30. Vahedi G, Takahashi H, Nakayamada S, Sun HW, Sartorelli V, Kanno Y, O'Shea JJ. STATs shape the active enhancer landscape of T cell populations. *Cell* 2012;151:981-993.
[PUBMED](#) | [CROSSREF](#)
31. Samstein RM, Arvey A, Josefowicz SZ, Peng X, Reynolds A, Sandstrom R, Neph S, Sabo P, Kim JM, Liao W, et al. Foxp3 exploits a pre-existent enhancer landscape for regulatory T cell lineage specification. *Cell* 2012;151:153-166.
[PUBMED](#) | [CROSSREF](#)

32. Chalmin F, Humblin E, Ghiringhelli F, Végran F. Transcriptional programs underlying Cd4 T cell differentiation and functions. *Int Rev Cell Mol Biol* 2018;341:1-61.
[PUBMED](#) | [CROSSREF](#)
33. Christie D, Zhu J. Transcriptional regulatory networks for CD4 T cell differentiation. *Curr Top Microbiol Immunol* 2014;381:125-172.
[PUBMED](#) | [CROSSREF](#)
34. Ciofani M, Madar A, Galan C, Sellars M, Mace K, Pauli F, Agarwal A, Huang W, Parkhurst CN, Muratet M, et al. A validated regulatory network for Th17 cell specification. *Cell* 2012;151:289-303.
[PUBMED](#) | [CROSSREF](#)
35. Yosef N, Shalek AK, Gaublotte JT, Jin H, Lee Y, Awasthi A, Wu C, Karwacz K, Xiao S, Jorgolli M, et al. Dynamic regulatory network controlling TH17 cell differentiation. *Nature* 2013;496:461-468.
[PUBMED](#) | [CROSSREF](#)
36. Fu W, Ergun A, Lu T, Hill JA, Haxhinasto S, Fassett MS, Gazit R, Adoro S, Glimcher L, Chan S, et al. A multiply redundant genetic switch 'locks in' the transcriptional signature of regulatory T cells. *Nat Immunol* 2012;13:972-980.
[PUBMED](#) | [CROSSREF](#)
37. Wilson CB, Rowell E, Sekimata M. Epigenetic control of T-helper-cell differentiation. *Nat Rev Immunol* 2009;9:91-105.
[PUBMED](#) | [CROSSREF](#)
38. Lee GR, Kim ST, Spilianakis CG, Fields PE, Flavell RA. T helper cell differentiation: regulation by cis elements and epigenetics. *Immunity* 2006;24:369-379.
[PUBMED](#) | [CROSSREF](#)
39. Wei G, Wei L, Zhu J, Zang C, Hu-Li J, Yao Z, Cui K, Kanno Y, Roh TY, Watford WT, et al. Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4⁺ T cells. *Immunity* 2009;30:155-167.
[PUBMED](#) | [CROSSREF](#)
40. Levings PP, Bungert J. The human β -globin locus control region. *Eur J Biochem* 2002;269:1589-1599.
[PUBMED](#) | [CROSSREF](#)
41. Lee GR, Fields PE, Griffin TJ 4th, Flavell RA. Regulation of the Th2 cytokine locus by a locus control region. *Immunity* 2003;19:145-153.
[PUBMED](#) | [CROSSREF](#)
42. Koh BH, Hwang SS, Kim JY, Lee W, Kang MJ, Lee CG, Park JW, Flavell RA, Lee GR. Th2 LCR is essential for regulation of Th2 cytokine genes and for pathogenesis of allergic asthma. *Proc Natl Acad Sci U S A* 2010;107:10614-10619.
[PUBMED](#) | [CROSSREF](#)
43. Hwang SS, Kim YU, Lee S, Jang SW, Kim MK, Koh BH, Lee W, Kim J, Souabni A, Buslinger M, et al. Transcription factor YY1 is essential for regulation of the Th2 cytokine locus and for Th2 cell differentiation. *Proc Natl Acad Sci U S A* 2013;110:276-281.
[PUBMED](#) | [CROSSREF](#)
44. Hwang SS, Jang SW, Lee KO, Kim HS, Lee GR. RHD6 coordinately regulates the Th2 cytokine genes by recruiting GATA3, SATB1, and IRF4. *Allergy* 2017;72:772-782.
[PUBMED](#) | [CROSSREF](#)
45. Lee GR, Spilianakis CG, Flavell RA. Hypersensitive site 7 of the TH2 locus control region is essential for expressing TH2 cytokine genes and for long-range intrachromosomal interactions. *Nat Immunol* 2005;6:42-48.
[PUBMED](#) | [CROSSREF](#)
46. Williams A, Lee GR, Spilianakis CG, Hwang SS, Eisenbarth SC, Flavell RA. Hypersensitive site 6 of the Th2 locus control region is essential for Th2 cytokine expression. *Proc Natl Acad Sci U S A* 2013;110:6955-6960.
[PUBMED](#) | [CROSSREF](#)
47. Spilianakis CG, Flavell RA. Long-range intrachromosomal interactions in the T helper type 2 cytokine locus. *Nat Immunol* 2004;5:1017-1027.
[PUBMED](#) | [CROSSREF](#)
48. Spilianakis CG, Lalioti MD, Town T, Lee GR, Flavell RA. Interchromosomal associations between alternatively expressed loci. *Nature* 2005;435:637-645.
[PUBMED](#) | [CROSSREF](#)
49. Kim LK, Esplugues E, Zorca CE, Parisi F, Kluger Y, Kim TH, Galjart NJ, Flavell RA. Oct-1 regulates IL-17 expression by directing interchromosomal associations in conjunction with CTCF in T cells. *Mol Cell* 2014;54:56-66.
[PUBMED](#) | [CROSSREF](#)

50. Hadjur S, Williams LM, Ryan NK, Cobb BS, Sexton T, Fraser P, Fisher AG, Merckenschlager M. Cohesins form chromosomal cis-interactions at the developmentally regulated IFNG locus. *Nature* 2009;460:410-413.
[PUBMED](#) | [CROSSREF](#)
51. Sekimata M, Pérez-Melgosa M, Miller SA, Weinmann AS, Sabo PJ, Sandstrom R, Dorschner MO, Stamatoyannopoulos JA, Wilson CB. CCCTC-binding factor and the transcription factor T-bet orchestrate T helper 1 cell-specific structure and function at the interferon-gamma locus. *Immunity* 2009;31:551-564.
[PUBMED](#) | [CROSSREF](#)
52. Murphy E, Shibuya K, Hosken N, Openshaw P, Maino V, Davis K, Murphy K, O'Garra A. Reversibility of T helper 1 and 2 populations is lost after long-term stimulation. *J Exp Med* 1996;183:901-913.
[PUBMED](#) | [CROSSREF](#)
53. Grogan JL, Mohrs M, Harmon B, Lacy DA, Sedat JW, Locksley RM. Early transcription and silencing of cytokine genes underlie polarization of T helper cell subsets. *Immunity* 2001;14:205-215.
[PUBMED](#) | [CROSSREF](#)
54. Ballesteros-Tato A, Randall TD, Lund FE, Spolski R, Leonard WJ, León B. T follicular helper cell plasticity shapes pathogenic T helper 2 cell-mediated immunity to inhaled house dust mite. *Immunity* 2016;44:259-273.
[PUBMED](#) | [CROSSREF](#)
55. Zhou L, Chong MM, Littman DR. Plasticity of CD4⁺ T cell lineage differentiation. *Immunity* 2009;30:646-655.
[PUBMED](#) | [CROSSREF](#)
56. Hirota K, Duarte JH, Veldhoen M, Hornsby E, Li Y, Cua DJ, Ahlfors H, Wilhelm C, Tolaini M, Menzel U, et al. Fate mapping of IL-17-producing T cells in inflammatory responses. *Nat Immunol* 2011;12:255-263.
[PUBMED](#) | [CROSSREF](#)
57. Bending D, De la Peña H, Veldhoen M, Phillips JM, Uyttenhove C, Stockinger B, Cooke A. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. *J Clin Invest* 2009;119:565-572.
[PUBMED](#) | [CROSSREF](#)
58. Muranski P, Borman ZA, Kerker SP, Klebanoff CA, Ji Y, Sanchez-Perez L, Sukumar M, Reger RN, Yu Z, Kern SJ, et al. Th17 cells are long lived and retain a stem cell-like molecular signature. *Immunity* 2011;35:972-985.
[PUBMED](#) | [CROSSREF](#)
59. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelletier A, Lafaille JJ, Cua DJ, Littman DR. The orphan nuclear receptor ROR γ t directs the differentiation program of proinflammatory IL-17⁺ T helper cells. *Cell* 2006;126:1121-1133.
[PUBMED](#) | [CROSSREF](#)
60. Okada S, Markle JG, Deenick EK, Mele F, Averbuch D, Lagos M, Alzahrani M, Al-Muhsen S, Halwani R, Ma CS, et al. Impairment of immunity to *Candida* and *Mycobacterium* in humans with bi-allelic RORC mutations. *Science* 2015;349:606-613.
[PUBMED](#) | [CROSSREF](#)
61. Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urdahl KB, Campbell DJ. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. *Nat Immunol* 2009;10:595-602.
[PUBMED](#) | [CROSSREF](#)
62. Wan YY, Flavell RA. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. *Nature* 2007;445:766-770.
[PUBMED](#) | [CROSSREF](#)
63. Zheng Y, Chaudhry A, Kas A, deRoos P, Kim JM, Chu TT, Corcoran L, Treuting P, Klein U, Rudensky AY. Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T_H2 responses. *Nature* 2009;458:351-356.
[PUBMED](#) | [CROSSREF](#)
64. Chaudhry A, Rudra D, Treuting P, Samstein RM, Liang Y, Kas A, Rudensky AY. CD4⁺ regulatory T cells control T_H17 responses in a Stat3-dependent manner. *Science* 2009;326:986-991.
[PUBMED](#) | [CROSSREF](#)
65. Roy S, Rizvi ZA, Awasthi A. Metabolic checkpoints in differentiation of helper T cells in tissue inflammation. *Front Immunol* 2019;9:3036.
[PUBMED](#) | [CROSSREF](#)
66. Almeida L, Dhillon-LaBrooy A, Carriche G, Berod L, Sparwasser T. CD4⁺ T-cell differentiation and function: unifying glycolysis, fatty acid oxidation, polyamines NAD mitochondria. *J Allergy Clin Immunol* 2021;148:16-32.
[PUBMED](#) | [CROSSREF](#)
67. Yang W, Yu T, Cong Y. CD4⁺ T cell metabolism, gut microbiota, and autoimmune diseases: implication in precision medicine of autoimmune diseases. *Precis Clin Med* 2022;5:pbac018.
[PUBMED](#) | [CROSSREF](#)

68. Xu K, Yin N, Peng M, Stamatiades EG, Chhangawala S, Shyu A, Li P, Zhang X, Do MH, Capistrano KJ, et al. Glycolytic ATP fuels phosphoinositide 3-kinase signaling to support effector T helper 17 cell responses. *Immunity* 2021;54:976-987.e7.
[PUBMED](#) | [CROSSREF](#)
69. Shi LZ, Wang R, Huang G, Vogel P, Neale G, Green DR, Chi H. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. *J Exp Med* 2011;208:1367-1376.
[PUBMED](#) | [CROSSREF](#)
70. Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF, Sullivan SA, Nichols AG, Rathmell JC. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4⁺ T cell subsets. *J Immunol* 2011;186:3299-3303.
[PUBMED](#) | [CROSSREF](#)
71. Wang R, Dillon CP, Shi LZ, Milasta S, Carter R, Finkelstein D, McCormick LL, Fitzgerald P, Chi H, Munger J, et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. *Immunity* 2011;35:871-882.
[PUBMED](#) | [CROSSREF](#)
72. Preston GC, Sinclair LV, Kaskar A, Hukelmann JL, Navarro MN, Ferrero I, MacDonald HR, Cowling VH, Cantrell DA. Single cell tuning of Myc expression by antigen receptor signal strength and interleukin-2 in T lymphocytes. *EMBO J* 2015;34:2008-2024.
[PUBMED](#) | [CROSSREF](#)
73. Man K, Kallies A. Synchronizing transcriptional control of T cell metabolism and function. *Nat Rev Immunol* 2015;15:574-584.
[PUBMED](#) | [CROSSREF](#)
74. McNamee EN, Korn Johnson D, Homann D, Clambey ET. Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function. *Immunol Res* 2013;55:58-70.
[PUBMED](#) | [CROSSREF](#)
75. Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y, Bordman Z, Fu J, Kim Y, Yen HR, et al. Control of T_H17/T_{reg} balance by hypoxia-inducible factor 1. *Cell* 2011;146:772-784.
[PUBMED](#) | [CROSSREF](#)
76. Doedens AL, Phan AT, Stradner MH, Fujimoto JK, Nguyen JV, Yang E, Johnson RS, Goldrath AW. Hypoxia-inducible factors enhance the effector responses of CD8⁺ T cells to persistent antigen. *Nat Immunol* 2013;14:1173-1182.
[PUBMED](#) | [CROSSREF](#)
77. Phan AT, Doedens AL, Palazon A, Tyrakis PA, Cheung KP, Johnson RS, Goldrath AW. Constitutive glycolytic metabolism supports CD8⁺ T cell effector memory differentiation during viral infection. *Immunity* 2016;45:1024-1037.
[PUBMED](#) | [CROSSREF](#)
78. Clever D, Roychoudhuri R, Constantinides MG, Askenase MH, Sukumar M, Klebanoff CA, Eil RL, Hickman HD, Yu Z, Pan JH, et al. Oxygen sensing by T cells establishes an immunologically tolerant metastatic niche. *Cell* 2016;166:1117-1131.e14.
[PUBMED](#) | [CROSSREF](#)
79. Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B, Worley PF, Kozma SC, Powell JD. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. *Immunity* 2009;30:832-844.
[PUBMED](#) | [CROSSREF](#)
80. Delgoffe GM, Pollizzi KN, Waickman AT, Heikamp E, Meyers DJ, Horton MR, Xiao B, Worley PF, Powell JD. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. *Nat Immunol* 2011;12:295-303.
[PUBMED](#) | [CROSSREF](#)
81. Lee K, Gudapati P, Dragovic S, Spencer C, Joyce S, Killeen N, Magnuson MA, Boothby M. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. *Immunity* 2010;32:743-753.
[PUBMED](#) | [CROSSREF](#)
82. Shrestha S, Yang K, Guy C, Vogel P, Neale G, Chi H. T_{reg} cells require the phosphatase PTEN to restrain T_H1 and T_{FFH} cell responses. *Nat Immunol* 2015;16:178-187.
[PUBMED](#) | [CROSSREF](#)
83. Huynh A, DuPage M, Priyadharshini B, Sage PT, Quiros J, Borges CM, Townamchai N, Gerriets VA, Rathmell JC, Sharpe AH, et al. Control of PI(3) kinase in T_{reg} cells maintains homeostasis and lineage stability. *Nat Immunol* 2015;16:188-196.
[PUBMED](#) | [CROSSREF](#)

84. Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. *Genes Dev* 2011;25:1895-1908.
[PUBMED](#) | [CROSSREF](#)
85. Meares GP, Qin H, Liu Y, Holdbrooks AT, Benveniste EN. AMP-activated protein kinase restricts IFN- γ signaling. *J Immunol* 2013;190:372-380.
[PUBMED](#) | [CROSSREF](#)
86. Gaublotte JT, Yosef N, Lee Y, Gertner RS, Yang LV, Wu C, Pandolfi PP, Mak T, Satija R, Shalek AK, et al. Single-cell genomics unveils critical regulators of Th17 cell pathogenicity. *Cell* 2015;163:1400-1412.
[PUBMED](#) | [CROSSREF](#)
87. Karmaus PW, Chen X, Lim SA, Herrada AA, Nguyen TM, Xu B, Dhungana Y, Rankin S, Chen W, Rosencrance C, et al. Metabolic heterogeneity underlies reciprocal fates of T_H17 cell stemness and plasticity. *Nature* 2019;565:101-105.
[PUBMED](#) | [CROSSREF](#)
88. Tortola L, Jacobs A, Pohlmeier L, Obermair FJ, Ampenberger F, Bodenmiller B, Kopf M. High-dimensional T helper cell profiling reveals a broad diversity of stably committed effector states and uncovers interlineage relationships. *Immunity* 2020;53:597-613.e6.
[PUBMED](#) | [CROSSREF](#)
89. Kiner E, Willie E, Vijaykumar B, Chowdhary K, Schmutz H, Chandler J, Schnell A, Thakore PI, LeGros G, Mostafavi S, et al. Gut CD4⁺ T cell phenotypes are a continuum molded by microbes, not by T_H archetypes. *Nat Immunol* 2021;22:216-228.
[PUBMED](#) | [CROSSREF](#)
90. Lönnberg T, Svensson V, James KR, Fernandez-Ruiz D, Sebina I, Montandon R, Soon MS, Fogg LG, Nair AS, Liligeto U, et al. Single-cell RNA-seq and computational analysis using temporal mixture modelling resolves Th1/Tfh fate bifurcation in malaria. *Sci Immunol* 2017;2:eal2192.
[PUBMED](#) | [CROSSREF](#)